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Abstract
Background: The sodium/iodide symporter (NIS) is a plasma membrane glycoprotein that
mediates iodide (I-) transport in the thyroid, lactating breast, salivary glands, and stomach.
Whereas NIS expression and regulation have been extensively investigated in healthy and
neoplastic thyroid and breast tissues, little is known about NIS expression and function along the
healthy and diseased gastrointestinal tract.
Methods:  Thus, we investigated NIS expression by immunohistochemical analysis in 155
gastrointestinal tissue samples and by immunoblot analysis in 17 gastric tumors from 83 patients.
Results:  Regarding the healthy Gl tract, we observed NIS expression exclusively in the
basolateral region of the gastric mucin-producing epithelial cells. In gastritis, positive NIS staining
was observed in these cells both in the presence and absence of Helicobacter pylori. Significantly,
NIS expression was absent in gastric cancer, independently of its histological type. Only focal
faint NIS expression was detected in the direct vicinity of gastric tumors, i.e., in the histologically
intact mucosa, the expression becoming gradually stronger and linear farther away from the
tumor. Barrett mucosa with junctional and fundic-type columnar metaplasia displayed positive
NIS staining, whereas Barrett mucosa with intestinal metaplasia was negative. NIS staining was
also absent in intestinalized gastric polyps.
Conclusion: That NIS expression is markedly decreased or absent in case of intestinalization
or malignant transformation of the gastric mucosa suggests that NIS may prove to be a significant
tumor marker in the diagnosis and prognosis of gastric malignancies and also precancerous
lesions such as Barrett mucosa, thus extending the medical significance of NIS beyond thyroid
disease.
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Background
Iodide (I-) is an essential constituent of the thyroid hor-
mones triiodothyronine (T3) and tetraiodothyronine (T4).
These hormones are vital for the normal development and
maturation of the central nervous system in the newborn
and for multiple metabolic functions in the adult. I-
metabolism in humans appears to have adapted to pro-
vide sufficient I- for normal thyroid function in the face of
the environmental scarcity of I-. A cornerstone of I- metab-
olism is active I- uptake in the thyroid, a process mediated
by the sodium/iodide symporter (NIS)[1,2]. NIS is an
integral plasma membrane glycoprotein located in the
basolateral membrane of the thyroid follicular cells[3].
Although NIS-mediated active I- uptake has long been
viewed as a distinctly thyroidal phenomenon, it is now
clear that active I- transport observed in extrathyroidal tis-
sues such as salivary glands, lactating mammary gland,
gastric mucosa, and placenta is also mediated by NIS [3-
8]. The NIS cDNA cloned from these tissues is identical to
thyroid NIS[5]. Indeed, deglycosylation with N-glycosi-
dase F or methionine-specific CNBr cleavage of thyroid,
stomach, and mammary gland NIS proteins has indicated
that NIS is the same protein in each of these tissues[6].
NIS-mediated radioiodide uptake in the stomach and sal-
ivary glands is routinely observed in radioiodide/99mTcO4
-whole-body scintiscans (Fig 1A) [9].
The supply of I- for thyroid hormone biosynthesis is gov-
erned by dietary I- intake, I- absorption, and thyroidal I-
uptake. I- is presumed to be absorbed in the small intes-
tine, but neither the anatomical location of its absorption
nor its mechanism has been identified. Interestingly, gas-
tric NIS mediates the active transport of I- from the blood-
stream to the gastric lumen, i.e., the active secretion of I-
into the gastric juice. Secreted I- is then recirculated into
the bloodstream when it is absorbed, along with newly
ingested dietary I-, in the small intestine. I- is ultimately
excreted mainly by the kidneys. The role of secreted I- in
the gastric juice is unknown, as is the function of NIS-
mediated I- secretion to the saliva in the salivary glands. By
contrast, the functional role of NIS-mediated I- transloca-
tion in the lactating mammary gland is crucial and very
clear: the process results in I- secretion to the milk, thus
supplying the anion to the breast-fed newborn for his/her
own thyroid hormone biosynthesis[6].
Data on NIS expression and function in regions of the gas-
trointestinal tract other than the stomach are still scant
and somewhat controversial. The presence of the NIS tran-
script, as detected by RT-PCR, has been reported in both
the colon[10] and the small intestine[11]. However, other
investigators have been unable to amplify the NIS tran-
script in either of these two tissues[5,12,13]. By immu-
noshistochemistry, Spitzweg et al[5], Lacroix et al [13],
and Wapnir et al [14] have observed some NIS protein
expression in the colon; in contrast, Vayre et al [15]
observed it only in the rectum but not in the rest of the
colon. None of the investigations carried out to date have
shown NIS expression in the esophagus[3]. Findings on
NIS expression in gastrointestinal tumors have also been
limited. Gastric carcinoma, unlike normal mucosa, has
generally been reported to exhibit no I- or pertechnetate
(99mTcO4 
-)accumulation [16-18] (pertechnetate is an
anion with the same size and charge as I- and is similarly
transported by NIS), with the sole exception of Wu et al
[19], who reported radioiodide uptake in gastric adeno-
carcinoma. In addition, in the 1960's and 70's, radioio-
dide or 99mTcO4 
-gastric scintigraphy was studied as a
possible method for the diagnosis of gastric neoplasia,
based on the finding that malignant gastric tissue failed to
transport I-or 99mTcO4 
-into the gastric juice [16-18]. Fur-
thermore, during the same decade, Berquist et al used
99mTcO4 
- scintigraphy to establish the diagnosis of Barrett
esophagus, based on the characteristic replacement of the
distal esophageal mucosa by the 99mTcO4 
-concentrating
gastric columnar epithelium[20,21]. These observations
suggest not only that NIS expression may be impaired as
a result of malignant transformation, but also that the
determination of NIS expression and function may be of
diagnostic value in gastroesophageal disease.
Consistent with the above concept is our recent report of
decreased or absent NIS expression in 27 gastric adenocar-
cinomas studied by high-density tissue microarrays[14].
Whereas tissue microarrays are optimal for high-through-
put screening, the sampling with tissue cores is limited
Thus, to expand our findings and more thoroughly exam-
ine the issue of NIS expression in gastroesophageal cancer
and its possible diagnostic value, we have analyzed NIS
expression in normal and malignant gastrointestinal tis-
sue samples from 83 patients. Samples were obtained dur-
ing surgical resection or endoscopic examination and
were analyzed by immunohistochemistry on conven-
tional tissue sections, given that this technique offers the
advantage (over RT-PCR) of determining expression and
cellular localization of the NIS protein instead of the NIS
transcript[22]. We also assessed NIS expression by immu-
noblot analysis to ascertain the specificity of the observed
immunoreactivity.
Methods
Snap frozen tissue samples were obtained for immunob-
lot analysis from 17 patients undergoing resections for
gastric tumors (3 MALT and 14 adenocarcinomas from 5
female and 12 male patients; average age: 62). Corre-
sponding normal peritumoral tissues were also collected.
We studied by immunohistochemistry tissue samples
obtained from the gastrointestinal tracts of 66 patients
(average age: 54; male/female ratio: 37/29). In the case ofBMC Cancer 2007, 7:5 http://www.biomedcentral.com/1471-2407/7/5
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NIS expression in different tissues Figure 1
NIS expression in different tissues. A: Radioiodide accumulation in NIS-expressing human tissues (SG: salivary glands, T: 
thyroid, G: stomach) 2 hours after 99mTc-pertechnetate administration (5 mCi). B: Immunoblot analyses of human NIS expres-
sion in a Graves' thyroid (T), normal salivary glands (SG), and normal gastric mucosa (G). Total protein (50 µg) was electro-
phoresed into each lane; the nitrocellulose membrane was probed with 3 nM affinity-purified anti-human-NIS Ab as described 
in Materials and Methods. C-H: Immunohistochemical analyses of NIS expression in human iodide-concentrating tissues. C: 
Normal thyroid (original magnification: 400 ×), D: Graves' thyroid, strong basolateral NIS staining of the follicular epithelial 
cells (original magnification: 1,000 ×), E: Salivary gland (original magnification: 400 ×), F: Basolateral NIS staining in the salivary 
ductal cells (original magnification: 1,000 ×), G: Gastric mucosa (original magnification: 400 ×), H: Basolateral NIS staining of the 
gastric mucin-secreting cells (original magnification: 1,000 ×).
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20 cancer patients, samples were taken from tumors and
their neighboring areas (tumor, tumor margin, and 1 cm
and more than 3 cm from the tumor margin) immediately
after resection in the operating theatre; the remaining 46
(66–20) were biopsies. Tissue samples from small and
large intestines were obtained from all segments of the
intestinal tract (jejunum, ileum, and right and left colon).
Permission for the investigation was obtained from the
local Ethical Committee of the St. George University
Teaching Hospital Székesfehérvár, Hungary.
Immunoblot
Tissue samples were blended for 1 min with a polytron
homogenizer (Brinkman Instruments, Westbury, New
York) and homogenized with a stirrer type glass-Teflon
homogenizer (Caframo-Wiarton, Ontario, Canada) in a
buffer containing 250 mM sucrose, 1 mM EDTA, 10 mM
Hepes (pH 7.5), and protease inhibitors (90 µg/ml apro-
tinin, 4 µg/ml leupeptin, 0.8 mM phenylmethanesulfonyl
fluoride). Membrane fractions were prepared as
described[23]. PAGE and electroblotting to nitrocellulose
were performed as previously described[23]. All samples
were diluted 1:2 with sample buffer and heated at 37°C
for 30 min prior to electrophoresis. Immunoblot analysis
was also carried out as described[23], with affinity-puri-
fied anti-human-NIS (-hNIS) Ab[6,14] (1 µg/µl) at a
1:2,000 dilution, and a 1:2,000 dilution of a horseradish-
peroxidase-linked donkey anti-rabbit IgG (Amersham).
Both incubations were performed for 1 h. Proteins were
visualized by the enhanced chemiluminescence (ECL)
Western blot detection system (Amersham).
Immunohistochemistry
All gastrointestinal tissue sections (3 µm) were deparaffi-
nated and rehydrated. All slides were subjected to antigen
retrieval by means of a 10%-citrate buffer. Washes were
done with TBST [0.3 M NaCI, 0.1% Tween 20, 0.05 M Tris-
HCI (pH 7.6)] for 5 min. Endogenous peroxide activity
was blocked with 5% H2O2  for 15 min. Endogenous
biotin activity was blocked with the DAKO Biotin Block-
ing System (Carpinteria, CA). Slides were incubated for 1
h with the affinity-purified polyclonal anti-human NIS
antibody generated against the last 16 amino acids of the
carboxy-terminal end of the protein[22]. The initial con-
centration of the Abs was 1 µg/µl; they were diluted in the
blocking solution 1:6,000. The Catalyzed Signal Amplifi-
cation kit (DAKO, Carpinteria, CA) was used for the
remainder of the procedure according to the supplier's
instructions. Salivary parotid gland was used as a positive
control and mesenteric lymph node as a negative control.
All slides were counterstained with hematoxylin.
Results
Immunohistochemical analysis of NIS in the thyroid, sal-
ivary glands, and stomach revealed very distinctly in
which particular cells NIS is located in each tissue, namely
the thyroid epithelial (Fig. 1C,D), salivary gland ductal
epithelial (Fig. 1E,F), and gastric mucin-producing epithe-
lial cells (Fig. 1G,H). In all three kinds of cells, NIS is
clearly observed in the basolateral plasma membrane. By
immunoblot analysis of membrane fractions, human NIS
was detected mainly as a fully glycosylated mature ~90–
120-kDa polypeptide in thyroid, salivary gland, and stom-
ach (Fig. 1B and Fig. 2). We have previously shown that in
rat tissues, NIS differences in electrophoretic mobility are
due to different degrees of glycosylation[6]. The partially
glycosylated ~50-kDa-precursor band and the ~180-kDa-
dimer band observed in thyroid tissue were also detected
in salivary glands and in the stomach upon longer expo-
sure.
We investigated NIS protein expression by immnunoblot
analysis in 17 gastric tumors (3 MALT and 14 adenocarci-
nomas) and in their corresponding peritumoral normal
tissues. Twelve tumors (71%) exhibited no NIS expression
and 5 (29%) of the tumoral tissues showed significantly
decreased NIS expression compared to that of normal gas-
tric mucosa (Table 1). Six peritumoral tissues displayed
NIS expression similar to that of normal mucosa, 4 exhib-
ited weak expression, and 7 lacked NIS expression alto-
gether. No MALT lesions displayed NIS staining;
interestingly, the normal mucosa in close proximity of the
tumor was also negative (Table 1 and Fig. 2).
To gain further insight into NIS expression in the digestive
tract, we analyzed NIS by immunohistochemistry in sam-
ples from different patients. A total of 155 tissue samples
obtained from the gastrointestinal tracts of 66 patients
(Table 2) was studied, including 42 esophageal, 53 gastric,
11 small-bowel, and 49 large-bowel tissue samples. NIS
expression was detected only in the gastric mucosa. More
specifically, we observed NIS expression in the basolateral
region of normal gastric mucosal surface epithelial cells in
the form of expressed, homogenous linear staining (Figs.
1G,H; and 3m). At the same time, we detected no NIS
expression in the mucin-containing cells of the neck of the
foveola, in the parietal and chief cells, or in the neuroen-
docrine cells. Similarly, the goblet, Paneth, and ciliated
epithelial cells of gastric intestinal metaplasia, as well as
the mucus-producing columnar cells of the colon and the
squamous esophageal epithelium, proved NIS negative
(Fig. 3b,q,t,w).
NIS expression was absent in gastric cancer, independ-
ently of its histological type [adenocarcinoma (n = 4), sig-
net-ring cell (n = 3), papillary (n = 1) and (Fig. 3i–q)]. NIS
expression was undetectable along the tumor margins in
more than half the cases and weakly focally present in the
remaining instances (Table 3). Even at a distance of 1 cm
from the tumor margin, NIS staining was weak and focalBMC Cancer 2007, 7:5 http://www.biomedcentral.com/1471-2407/7/5
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in all cases in contrast to that in normal gastric mucosa
(Figs. 2G,H and 3k,I). The characteristic linear plasma
membrane expression pattern was detected only far from
the tumor (Fig. 3m), indicating that NIS expression is lost
in the vicinity of the cancer.
Nine out often hyperplastic gastric polyps were NIS-posi-
tive (Fig. 3n,o), the only negative being a colon-type meta-
plasia (Fig. 3p,q). The findings in samples from patients
with Barrett esophagus were striking: five junctional and
fundus-type columnar metaplasias were NIS positive (Fig.
3c,d), whereas five showing intestinal metaplasia were
consistently negative (Fig. 3e,f).
The samples from patients with gastritis displayed NIS
expression independently of the presence (4/6) or
absence (2/6) of Helicobacter pylori (Table 2).
Discussion
The field of extrathyroidal I- transport has changed consid-
erably since the extensive review published on the topic in
1961 by Brown-Grant. The main vertebrate nonthyroid
tissues reported to accumulate I- actively via NIS are the
salivary glands, gastric mucosa, lactating mammary gland,
placenta, choroid plexus, and ciliary body of the
eye[3,4,8,24]. With the exception of the lactating mam-
mary gland, the physiological role of I- or other anions
transported by NIS in extrathyroidal tissues is unknown.
These tissue-specific NIS-mediated transport systems
exhibit functional similarities to their thyroid counter-
part, such as a Km for I- ranging from 10 to 30 µM and sus-
ceptibility to inhibition by perchlorate (CIO4 
-). In
contrast to TSH-regulated thyroid NIS and lactationally
regulated mammary gland NIS, both salivary and gastric
NIS are constitutively expressed[6,25,26]. NIS has been
detected in the basolateral membrane of all ductal epithe-
lial cells in the salivary gland[6], and in the basolateral
membrane of superficial mucin-secreting epithelial cells
in the stomach[6,13,15,27]. Although Spitzweg et al [27]
reported NIS-specific immunostaining in parietal cells, we
observed NIS expression exclusively in surface epithelial
cells. Wapnir et al [14] have reported some NIS expression
in a limited number of colon samples, but no NIS expres-
sion in colon was detected in the present study by either
immunohistochemistry or immunoblot (not shown).
There are at least three possible explanations for this dis-
crepancy: NIS expression may be focal rather than wide-
spread along the large bowel, variations in fixation
Immunoblot analysis of gastric NIS expression in human gastric tumors (T) and normal peritumoral tissues (N) Figure 2
Immunoblot analysis of gastric NIS expression in human gastric tumors (T) and normal peritumoral tissues 
(N). A, B, and D: adenocarcinoma, C: MALT lymphoma.
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Table 1: Immunoblot analysis of Na+/l- symporter protein expression in gastric tumors
Case N° Histology Gender Age Immunoblot tumor Immunoblot 
normal mucosa
1 adenocarcinoma M 71 - -
2 MALT lymphoma F 65 - -
3 MALT lymphoma F 70 - -
5 adenocarcinoma F 54 - -
7 adenocarcinoma F 30 - +
8 adenocarcinoma M 71 - -
9 adenocarcinoma M 69 - +
10 MALT lymphoma F 68 - +++
11 adenocarcinoma M 71 + +++
12 adenocarcinoma M 74 + +++
13 adenocarcinoma M 61 - -
19 adenocarcinoma M 46 + +
20 adenocarcinoma M 50 + +++
27 adenocarcinoma M 66 - +
28 adenocarcinoma M 68 - +++
29 adenocarcinoma M 61 - +++
35 adenocarcinoma M 62 + -
Table 2: NIS expression in normal and diseased human gastro-intestinal tissues
Number of samples NIS (+) NIS (-)
Esophagus 42
- normal mucosa 4 0 (0 %) 4 (100 %)
-squamous cell carcinoma* 6 0 (0 %) 6 (100 %)
-adenocarcinoma 4 0 (0 %) 4 (100 %)
- Barrett – junctional/fundus type 5 5 (100 %) 0 (0 %)
- Barrett – intestinal metaplasia 5 0 (0 %) 5 (100 %)
Stomach 53
- normal 8 8 (100 %) 0 (0 %)
-adenocarcinoma* 8 0 (0 %) 8 (100 %)
-polyp (hyperplastic) 10 9 (90 %) 1 (10 %)
-gastritis 6 6 (100 %) 0 (0 %)
Small intestine 11
-normal 4 0 (0 %) 4 (100 %)
-inflammation 3 0 (0 %) 3 (100 %)
-polyp 2 0 (0 %) 2 (100 %)
-adenocarcinoma 2 0 (0 %) 2 (100 %)
Colon 49
-normal 8 0 (0 %) 8 (100 %)
-inflammation 3 0 (0 %) 3 (100 %)
-polyp 9 0 (0 %) 9 (100 %)
-adenocarcinoma* 8 0 (0 %) 8 (100 %)
* Samples obtained from the corresponding peritumoral tissues are shown in Table 3; however, they are included in the total number of samples in 
this table.BMC Cancer 2007, 7:5 http://www.biomedcentral.com/1471-2407/7/5
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Immunohistochemical analysis of NIS expression in human gastrointestinal tract Figure 3
Immunohistochemical analysis of NIS expression in human gastrointestinal tract. a: normal esophageal squamous 
epithelium (haematoxylin-eosin/HE/staining, original magnification 100×) b: normal esophageal squamous epithelium: negative 
for NIS expression (original magnification 100×) c: Barrett mucosa (HE staining, original magnification 100×) d: Barrett mucosa, 
junctional and fundus-type columnar metaplasia: NIS positive staining (original magnification 100×) e: Barrett mucosa with 
intestinal metaplasia (HE staining, original magnification 100×) f: Barrett mucosa with intestinal metaplasia: negative for NIS 
expression (original magnification 100×) g: squamous cell esophageal carcinoma (HE staining, original magnification 100×) h: 
squamous cell esophageal carcinoma: NIS negative staining (original magnification 100×) i: gastric carcinoma – signet ring cell – 
(HE staining, original magnification 200×) j: gastric carcinoma – signet ring cell – negative for NIS expression (original magnifica-
tion 200×) k: on the border of the gastric adenocarcinoma, adjacent "normal" extratumoral mucosa: faint, focal NIS expression 
(original magnification 100×) I: at 1 cm from gastric adenocarcinoma: definite focal NIS staining (original magnification 400×) m: 
far from the gastric adenocarcinoma: strong, linear NIS expression (original magnification 400×) n: gastric polyp (HE staining, 
original magnification 100×) o: gastric polyp: NIS positive staining (original magnification 100×) p: gastric polyp (HE staining, 
original magnification 200×) q: gastric polyp with colon-type metaplasia: NIS negative staining (original magnification 200×) r: 
small bowel adenocarcinoma (HE staining, original magnification 100×) s: small bowel adenocarcinoma: NIS negative staining 
(original magnification 100×) t: normal large bowel mucosa: NIS negative staining (original magnification 100×) v: colon polyp 
(HE staining, original magnification 100×) w: colon polyp: NIS negative expression (original magnification 100×) x: adenocarci-
noma of the colon (HE staining, original magnification 100×) y: adenocarcinoma of the colon: negative for NIS expression (orig-
inal magnification 100×).
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methods may alter tissue antigenicity, or microarray over-
staining may result from the "edge effect" of the small tis-
sue cores.
NIS transports other anions with the following relative
apparent affinities: I- (1.00) ≥ SeCN- (0.87) > SCN- (0.34)
> CIO3 
-(0.12) > NO3 
- (0.04)[28]. As indicated earlier, the
roles of I- or other anions secreted to the lumen of the gas-
trointestinal system by the constitutively expressed sali-
vary and gastric NIS are unknown. I- concentrated in the
gastric juice is reabsorbed in the small intestine and used
for thyroid hormone biosynthesis by the thyroid or
excreted by glomerular filtration through the kidney.
Albeit with a lower affinity than I-, nitrate (NO3 
-) is one
of the other anions transported by NIS. Nitrate can be
reduced to nitrite (NO2 
-) by facultative anaerobic bacte-
ria, and it can be acidified in the stomach, generating
nitric oxide (NO), which has a strong bactericidal
effect[29,30]. Indeed, acidified NO2 
-  is bactericidal
against H. pylori[31]; this effect is amplified by thiocy-
anate (SCN-), another NIS substrate[32]. H. pylori is fre-
quently found in patients with gastric ulcers, suggesting a
possible causative role for this bacteria[33]. Thus, one
may speculate that if NIS-mediated NO3 
- secretion occurs
in the stomach, NIS function might play a role in contain-
ing or preventing H. pylori-linked gastric ulcers or chronic
gastritis. However, we observed no changes in NIS expres-
sion in samples from patients with gastritis as compared
to normal subjects, irrespective of whether H. pylori was
present.
NIS expression and function have been investigated in
both thyroid and breast cancers. Whereas NIS expression
is absent or decreased in 30% of thyroid cancers, NIS is
actually overexpressed but not properly targeted to the
plasma membrane in the remaining 70%[14,22]. Signifi-
cantly, over 70% of human breast cancers express NIS,
raising the prospect of the possible use of radioiodide in
the diagnosis and treatment of breast cancer[6], as is rou-
tinely and successfully done in the treatment of NIS-
expressing thyroid cancer.
We ascertained NIS expression in gastrointestinal tumors
by carrying out immunohistochemical analysis on biop-
sies obtained from 66 patients, partly during surgical
interventions and partly during endoscopical examina-
tions. In addition, 17 surgical samples were investigated
by immunoblot analysis. We detected no NIS staining in
patients with intestinalization or gastric cancer, indicating
that malignant transformation is linked to decreased or
suppressed NIS expression. Interestingly, the focal NIS
staining observed in the direct vicinity of gastric tumors
increased gradually and became linear as we proceeded
away from the tumor. This suggests that loss of NIS
expression may precede microscopically identifiable mor-
phological changes. One could speculate that NIS expres-
sion in the apparently normal gastric mucosa could be
used to define the true healthy margin, thus becoming a
potentially useful indicator to decrease local/anastomotic
recurrences.
In junctional and fundus-type columnar metaplasia Bar-
rett mucosa, NIS expression was intact; in contrast, in Bar-
ret mucosa with intestinalization, NIS expression was
absent. A similar phenomenon was observed in hyper-
plastic gastric polyps with intestinal metaplasia. These
Table 3: NIS expression in gastrointestinal tumors and adjacent tissues
Localization of the samples Number of samples NIS (+) NIS (-)
linear expression focal expression
distinct faint
ESOPHAGUS
Tumor 6 - - - 6
Border 6 - - - 6
1 cm distance 6 - - - 6
≥ 3 cm distance 6 3* 1* - 2
STOMACH
Tumor 7 - - - 7
Border 7 - 1 2 4
1 cm distance 7 - 2 5 -
≥ 3 cm distance 7 1 4 2 -
COLON
Tumor 7 - - - 7
Border 7 - - - 7
1 cm distance 7 - - - 7
≥ 3 cm distance 7 - - - 7
(*gastro-esophageal junction)BMC Cancer 2007, 7:5 http://www.biomedcentral.com/1471-2407/7/5
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data provide the molecular explanation for the 99mTcO4 
-
scintigraphic results from 30 years ago[16-18,20,21].
Conclusion
Taken together, our findings underscore the prognostic
and diagnostic significance of the absence of NIS expres-
sion in gastric alterations when intestinalization or cancer
occurs. This is especially true in Barrett metaplasia, since
the junctional and fundus-type metaplasias, in which NIS
is normally expressed, pose a much lower risk of malig-
nant transformation than intestinal metaplasia, which
exhibits no NIS expression and gives rise to a higher
number of dysplastic alterations and adenocarcinomas
even in small (i.e., <3-cm) lesions[34]. In conclusion, this
research suggests that the introduction of NIS immuno-
histochemical tests in gastric mucosa samples may be of
considerable diagnostic value in Barrett esophageal and
gastric polyps to evaluate intestinal metaplasia, and as an
additional early molecular marker in the diagnosis of pre-
cancerous or/and cancerous gastroesophageal lesions.
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
OD and NC conceived the study, AA, OD and NC
designed the study and drafted the manuscript, OD and
NC generated the NIS Abs and established the protocol for
NIS immunohistochemistry, AA and ASZ collected the
samples and carried out immunohistochemistries, OD
and MP performed immunoblots, IW performed pertech-
netate imaging. All authors read and approved the final
manuscript.
Acknowledgements
Grant support: NIH DK-41544 (NC).
References
1. Dai G, Levy O, Carrasco N: Cloning and characterization of the
thyroid iodide transporter.  Nature 1996, 379:458-60.
2. Smanik PA, Liu Q, Furminger TL, Ryu K, Xing S, Mazzaferri EL, Jhiang
SM: Cloning of the human sodium Iodide symporter.  Biochem
Biophys Res Commun 1996, 226:339-45.
3. Dohan O, De la Vieja A, Paroder V, Riedel C, Artani M, Reed M, Gin-
ter CS, Carrasco N: The sodium/iodide Symporter (NIS): char-
acterization, regulation, and medical significance.  Endocr Rev
2003, 24:48-77.
4. Brown-Grant K: Extrathyroidal iodide concentrating mechan-
ims.  Physiological Reviews 1961, 41:189-213.
5. Spitzweg C, Joba W, Eisenmenger W, Heufelder AE: Analysis of
human sodium iodide symporter gene expression in extrath-
yroidal tissues and cloning of its complementary deoxyribo-
nucleic acids from salivary gland, mammary gland, and
gastric mucosa.  J Clin Endocrinol Metab 1998, 83:1746-51.
6. Tazebay UH, Wapnir IL, Levy O, Dohan O, Zuckier LS, Zhao QH,
Deng HF, Amenta PS, Fineberg S, Pestell RG, et al.: The mammary
gland iodide transporter is expressed during lactation and in
breast cancer.  Nat Med 2000, 6:871-8.
7. Bidart JM, Lacroix L, Evain-Brion D, Caillou B, Lazar V, Frydman R,
Bellet D, Filetti S, Schlumberger M: Expression of Na+/l-sym-
porter and Pendred syndrome genes in trophoblast cells.  J
Clin Endocrinol Metab 2000, 85:4367-72.
8. Logothetopoulos J, Scott RF: Active iodide transport across the
placenta of the guinea-pig, rabbit and rat.  J Physiol 1956,
132:365-71.
9. Bruno R, Giannasio P, Ronga G, Baudin E, Travagli JP, Russo D, Filetti
S, Schlumberger M: Sodium iodide symporter expression and
radioiodine distribution in extrathyroidal tissues.  J Endocrinol
Invest 2004, 27:1010-4.
10. Smanik PA, Ryu KY, Theil KS, Mazzaferri EL, Jhiang SM: Expression,
exonintron organization, and chromosome mapping of the
human sodium iodide symporter.  Endocrinology 1997,
138:3555-8.
11. Perron B, Rodriguez AM, Leblanc G, Pourcher T: Cloning of the
mouse sodium iodide symporter and its expression in the
mammary gland and other tissues.  J Endocrinol 2001,
170:185-96.
12. Ajjan RA, Kamaruddin NA, Crisp M, Watson PF, Ludgate M, Weet-
man AP: Regulation and tissue distribution of the human
sodium iodide symporter gene.  Clin Endocrinol (Oxf) 1998,
49:517-23.
13. Lacroix L, Mian C, Caillou B, Talbot M, Filetti S, Schlumberger M,
Bidart JM: Na(+)/l(-) symporter and Pendred syndrome gene
and protein expressions in human extra-thyroidal tissues.
Eur J Endocrinol 2001, 144:297-302.
14. Wapnir IL, van de Rijn M, Nowels K, Amenta PS, Walton K, Mont-
gomery K, Greco RS, Dohan O, Carrasco N: Immunohistochem-
ical profile of the sodium/iodide symporter in thyroid,
breast, and other carcinomas using high density tissue
microarrays and conventional sections.  J Clin Endocrinol Metab
2003, 88:1880-8.
15. Vayre L, Sabourin JC, Caillou B, Ducreux M, Schlumberger M, Bidart
JM: Immunohistochemical analysis of Na+/l- symporter dis-
tribution in human extra-thyroidal tissues.  Eur J Endocrinol
1999, 141:382-6.
16. Marsden DS, Alexander CH, Yeung PK, Dunn AA: The use of 99 m
Tc to detect gastric malignancy.  Am J Gastroenterol 1973,
59:410-5.
17. Engelhart G, Fridrich R: [Physiological and pathological findings
in the use of technetium 99 m for gastric scintigraphy].  Sch-
weiz Med Wochenschr 1968, 98:301-4.
18. Fridrich R, Engelhart G: [The value of stomach scintigraphy
with technetium 99 m as a routine diagnostic procedure].
Schweiz Med Wochenschr 1968, 98:1789-93.
19. Wu SY, Kollin J, Coodley E, Lockyer T, Lyons KP, Moran E, Parker
LN, Yu AC: I-131 total-body scan: localization of disseminated
gastric adenocarcinoma. Case report and survey of the liter-
ature.  J Nucl Med 1984, 25:1204-9.
20. Berquist TH, Nolan NG, Stephens DH, Carlson HC: Radioisotope
scintigraphy in diagnosis of Barrett's esophagus.  Am J Roentge-
nol Radium Ther NucI Med 1975, 123:401-11.
21. Berquist TH, Nolan NG, Carlson HC, Stephens DH: Diagnosis of
Barrett's esophagus by pertechnetate scintigraphy.  Mayo Clin
Proc 1973, 48:276-9.
22. Dohan O, Baloch Z, Banrevi Z, Livolsi V, Carrasco N: Rapid com-
munication: predominant intracellular overexpression of the
Na(+)/l(-) symporter (NIS) in a large sampling of thyroid can-
cer cases.  J Clin Endocrinol Metab 2001, 86:2697-700.
23. Levy O, Dai G, Riedel C, Ginter CS, Paul EM, Lebowitz AN, Carrasco
N: Characterization of the thyroid Na+/l- symporter with an
anti-COOH terminus antibody.  Proc Natl Acad Sci USA 1997,
94:5568-73.
24. De La Vieja A, Dohan O, Levy O, Carrasco N: Molecular analysis
of the sodium/iodide symporter: impact on thyroid and
extrathyroid pathophysiology.  Physiol Rev 2000, 80:1083-105.
25. Riedel C, Levy O, Carrasco N: Post-transcriptional regulation of
the sodium/iodide symporter by thyrotropin.  J Biol Chem 2001,
276:21458-63.
26. Ohno M, Zannini M, Levy O, Carrasco N, di Lauro R: The paired-
domain transcription factor Pax8 binds to the upstream
enhancer of the rat sodium/iodide symporter gene and par-
ticipates in both thyroid-specific and cyclic-AMP-dependent
transcription.  Mol Cell Biol 1999, 19:2051-60.
27. Spitzweg C, Joba W, Schriever K, Goellner JR, Morris JC, Heufelder
AE: Analysis of human sodium iodide symporter immunore-Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Cancer 2007, 7:5 http://www.biomedcentral.com/1471-2407/7/5
Page 10 of 10
(page number not for citation purposes)
activity in human exocrine glands.  J Clin Endocrinol Metab 1999,
84:4178-84.
28. Eskandari S, Loo DD, Dai G, Levy O, Wright EM, Carrasco N: Thy-
roid Na+/l-symporter. Mechanism, stoichiometry, and spe-
cificity.  J Biol Chem 1997, 272:27230-8.
29. Gladwin MT: Haldane, hot dogs, halitosis, and hypoxic vasodi-
lation: the emerging biology of the nitrite anion.  J Clin Invest
2004, 113:19-21.
30. Benjamin N, O'Driscoll F, Dougall H, Duncan C, Smith L, Golden M,
McKenzie H: Stomach NO synthesis.  Nature 1994, 368:502.
31. Dykhuizen RS, Fraser A, McKenzie H, Golden M, Leifert C, Benjamin
N: Helicobacter pylori is killed by nitrite under acidic condi-
tions.  Gut 1998, 42:334-7.
32. Fite A, Dykhuizen R, Litterick A, Golden M, Leifert C: Effects of
ascorbic acid, glutathione, thiocyanate, and iodide on antimi-
crobial activity of acidified nitrite.  Antimicrob Agents Chemother
2004, 48:655-8.
33. Blaser MJ, Atherton JC: Helicobacter pylori persistence: biology
and disease.  J Clin Invest 2004, 113:321-33.
34. Wild CP, Hardie LJ: Reflux, Barrett's oesophagus and adeno-
carcinoma: burning questions.  Nat Rev Cancer 2003, 3:676-84.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2407/7/5/prepub